Carregant...
Multinucleation and Mesenchymal-to-Epithelial-Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer
Patients with metastatic castration resistant prostate cancer (mCRPC) frequently develop therapeutic resistance to taxane chemotherapy and antiandrogens. Cabazitaxel (CBZ) is a second-line taxane chemotherapeutic agent that provides additional survival benefits to patients with advanced disease. In...
Guardat en:
| Publicat a: | Cancer Res |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4755804/ https://ncbi.nlm.nih.gov/pubmed/26645563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-2078 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|